Market reviews 2015

Market review on human pharmaceuticals 2015

Published on 2 February 2016

Finland is the most important individual market for Orion, generating about one-third of the total net sales. According to IMS Health statistics, Finnish wholesale of human pharmaceuticals in 2015 was up by 3% on the previous year at EUR 2,239 (2,167) million. Orion was able to increase its sales faster than market growth, and maintained its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by IMS Health, Orion’s wholesale of human pharmaceuticals in Finland in 2015 amounted to EUR 270 (251) million, up by 7% compared with the previous year. Orion’s market share of Finnish pharmaceuticals markets was 12% (12%).

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s branded Parkinson’s drugs containing entacapone (Stalevo®, Comtess® and Comtan®) account for less than 15% of the Group’s net sales.

Total sales of all Parkinson’s drugs:

 

EUR or USD million

 

MAT9/2015

MAT9/2014

Change %

United States

USD

838

812

+3%

Europe TOP 5

EUR

944

995

-5%

Japan

EUR

556

497

+12%

Source: IMS Health pharmaceutical sales statistics MAT9/2015 (10/2014–9/2015)

 

The five largest European markets for Parkinson’s disease drugs were Germany, the United Kingdom, France, Spain and Italy.

 

Total sales of all Parkinson’s drugs containing entacapone:

 

EUR or USD million

 

MAT9/2015

MAT9/2014

Change %

United States

USD

89

118

-28%

Europe TOP 5

EUR

131

147

-11%

Japan

EUR

63

53

+19%

Source: IMS Health pharmaceutical sales statistics MAT9/2015 (10/2014–9/2015)

 

Total sales of Orion’s branded Parkinson’s drugs:

 

EUR or USD million

 

MAT9/2015

MAT9/2014

Change %

United States

USD

18

19

-5%

Europe TOP 5

EUR

102

127

-19%

Japan

EUR

63

53

+19%

Source: IMS Health pharmaceutical sales statistics MAT9/2015 (10/2014–9/2015)

 

Salesof Orion’s branded Parkinson’s drugs decreased in the United States due to the trend to generics in the market and in Europe due to commencement of generic competition. Sales in Japan increased mainly because Stalevo was launched in that market during 2015. The market share of Orion’s branded Parkinson’s drugs was 2% in the United States, on average 11% in the five largest European markets and 11% in Japan.

 

According to IMS Health pharmaceutical sales statistics, in Europe total sales of the most common intravenous anaesthetics and intensive care sedatives (propofol, midazolam, remifentanil and dexmedetomidine) in the 12-month period ending in September 2015 were up by 4% at EUR 519 (498) million. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in September 2015 sales of Orion’s Dexdor® intensive care sedative (dexmedetomidine) were up by 32% at EUR 34 (26) million in Europe.

 

Published on 27 October 2015

Finland is the most important individual market for Orion, generating about one-third of the total net sales. According to IMS Health statistics, Finnish wholesale of human pharmaceuticals in January–September 2015 was up by 3% on the previous year at EUR 1,620 (1,581) million. Orion was able to increase its sales faster than market growth, and maintained its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by IMS Health, Orion’s wholesale of human pharmaceuticals in Finland in January–September 2015 amounted to EUR 195 (183) million, up by 7% compared with the previous year. Orion’s market share of Finnish pharmaceuticals markets was 12% (12%).

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s branded Parkinson’s drugs containing entacapone (Stalevo®, Comtess® and Comtan®) account for about one-sixth of the Group’s net sales.

Total sales of all Parkinson’s drugs:

 

EUR or USD million

 

MAT6/2015

MAT6/2014

Change %

United States

USD

821

811

+1%

Europe TOP 5

EUR

958

994

-4%

Japan

EUR

543

491

+10%

Source: IMS Health pharmaceutical sales statistics MAT6/2015 (7/2014–6/2015)

 

The five largest European markets for Parkinson’s disease drugs were Germany, the United Kingdom, France, Spain and Italy.

 

Total sales of all Parkinson’s drugs containing entacapone:

 

EUR or USD million

 

MAT6/2015

MAT6/2014

Change %

United States

USD

93

129

-28%

Europe TOP 5

EUR

135

149

-9%

Japan

EUR

60

53

+12%

Source: IMS Health pharmaceutical sales statistics MAT6/2015 (7/2014–6/2015)

 

Total sales of Orion’s branded Parkinson’s drugs:

 

EUR or USD million

 

MAT6/2015

MAT6/2014

Change %

United States

USD

18

21

-15%

Europe TOP 5

EUR

109

129

-15%

Japan

EUR

60

53

+12%

Source: IMS Health pharmaceutical sales statistics MAT6/2015 (7/2014–6/2015)

 

Salesof Orion’s branded Parkinson’s drugs decreased in the United States due the trend to generics in the market and in Europe due to commencement of generic competition. Sales in Japan increased mainly because Stalevo was launched in that market during 2015. The market share of Orion’s branded Parkinson’s drugs was 2% in the United States, on average 11% in the five largest European markets and 11% in Japan.

 

According to IMS Health pharmaceutical sales statistics, in Europe total sales of the most common intravenous anaesthetics and intensive care sedatives (propofol, midazolam, remifentanil and dexmedetomidine) in the 12-month period ending in June 2015 were up by 3% at EUR 515 (498) million. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in June 2015 sales of Orion’s Dexdor® intensive care sedative (dexmedetomidine) were up by 35% at EUR 32 (24) million in Europe.

 

Published on 28 July 2015

Finland is the most important individual market for Orion, generating about one-third of the total net sales. According to IMS Health statistics, Finnish wholesale of human pharmaceuticals in January–June 2015 was up by 2% on the previous year at EUR 1,071 (1,048) million. Orion was able to increase its sales faster than market growth, and maintained its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by IMS Health, Orion’s wholesale of human pharmaceuticals in Finland in January–June 2015 amounted to EUR 129 (121) million, up by 7% compared with the previous year. Orion’s market share of Finnish pharmaceuticals markets was 12% (12%). 

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s branded Parkinson’s drugs containing entacapone (Stalevo®, Comtess® and Comtan®) account for about one-sixth of the Group’s net sales.

Total sales of all Parkinson’s drugs:

EUR or USD million

 

MAT3/2015

MAT3/2014

Change %

United States

USD

806

803

+0%

Europe TOP 5

EUR

976

991

-2%

Japan

EUR

521

494

+6%

 Source: IMS Health pharmaceutical sales statistics MAT3/2015 (4/2014-3/2015)

 

The five largest European markets for Parkinson’s disease drugs were Germany, the United Kingdom, France, Spain and Italy.

 

Total sales of all Parkinson’s drugs containing entacapone: 

EUR or USD million

 

MAT3/2015

MAT3/2014

Change %

United States

USD

100 

138

-28%

Europe TOP 5

EUR

140

150

-7%

Japan

EUR

55

55

+1%

 Source: IMS Health pharmaceutical sales statistics MAT3/2015 (4/2014-3/2015)

Total sales of Orion’s branded Parkinson’s drugs: 

EUR or USD million

 

MAT3/2015

MAT3/2014

Change %

United States

USD

16 

24

-31%

Europe TOP 5

EUR

117

129

-10%

Japan

EUR

55

55

+1%

Source: IMS Health pharmaceutical sales statistics MAT3/2015 (4/2014-3/2015)

Sales of Orion’s branded Parkinson’s drugs decreased in the United States due the trend to generics in the market and in Europe due to commencement of generic competition. The market share of Orion’s branded Parkinson’s drugs was 2% in the United States, on average 12% in the five largest European markets and 11% in Japan. 

According to IMS Health pharmaceutical sales statistics, in Europe total sales of the most common intravenous anaesthetics and intensive care sedatives (propofol, midazolam, remifentanil and dexmedetomidine) in the 12-month period ending in March 2015 were up by 3% at EUR 509 (495) million. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in March 2015 sales of Orion’s Dexdor® intensive care sedative (dexmedetomidine) were up by 37% at EUR 30 (22) million in Europe.

 

Published on 29 April 2015

Finland is the most important individual market for Orion, generating about one-quarter of the total net sales. According to IMS Health statistics, Finnish wholesale of human pharmaceuticals in 2014 was up by 5% on the previous year at EUR 2,167 (2,070) million. Orion was able to increase its sales and maintained its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by IMS Health, Orion’s wholesale of human pharmaceuticals in Finland in 2014 amounted to EUR 251 (233) million, up by 8% compared with the previous year. Orion’s market share of Finnish pharmaceuticals markets was 12% (11%). 

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s branded Parkinson’s drugs containing entacapone (Stalevo®, Comtess® and Comtan®) accounted for about one-sixth of the Group’s net sales in 2014.

Total sales of all Parkinson’s drugs:

EUR or USD million

 

MAT9/2014

MAT9/2013

Change %

United States

USD

810

751

+8%

Europe TOP 5

EUR

996

978

+2%

Japan

EUR

497

523

-5%

Source: IMS Health pharmaceutical sales statistics MAT9/2014

The five largest European markets for Parkinson’s disease drugs were Germany, the United Kingdom, France, Spain and Italy. The size of the Japanese market as a whole decreased due to depreciation of the yen exchange rate. Measured in terms of local currency, sales of Orion’s Parkinson’s drugs grew in Japan.

Total sales of all Parkinson’s drugs containing entacapone:

EUR or USD million

 

MAT9/2014

MAT9/2013

Change %

United States

USD

119

153

-22%

Europe TOP 5

EUR

147

153

-4%

Japan

EUR

53

59

-10%

Source: IMS Health pharmaceutical sales statistics MAT9/2014

Total sales of Orion’s branded Parkinson’s drugs:

EUR or USD million

 

MAT9/2014

MAT9/2013

Change %

United States

USD

20

37

-47%

Europe TOP 5

EUR

127

131

-4%

Japan

EUR

53

59

-10%

Source: IMS Health pharmaceutical sales statistics MAT9/2014

Sales of Orion’s branded Parkinson’s drugs decreased in the United States due the trend to generics in the market and in Japan due to depreciation of the yen exchange rate. The market share of Orion’s branded Parkinson’s drugs was 2% in the United States, on average 13% in the five largest European markets and 11% in Japan. 

According to IMS Health pharmaceutical sales statistics, sales of Precedex® intensive care sedative (dexmedetomidine) were up by 10% at USD 401 million in the 12-month period ending in September 2014 (USD 365 million in the previous 12-month period). The largest market, with sales of USD 335 (305) million, was the United States, where Precedex sales grew by 10%. IMS Health pharmaceutical sales statistics have become more comprehensive as regards reporting of Precedex, following which the figures for the reported period and comparative period are greater than as previously. Generic competition to Precedex in the United States commenced in August 2014, but the effect of competition was not yet significant in the figures reported by IMS Health for the period ending in September 2014.

According to IMS Health pharmaceutical sales statistics, total sales of the most common intravenous anaesthetics and intensive care sedatives (propofol, midazolam, remifentanil and dexmedetomidine) in Europe in the 12-month period ending in September 2014 were up by 3% at EUR 490 (476) million. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in September 2014 sales of Orion’s Dexdor® intensive care sedative (dexmedetomidine) were up by 29% at EUR 26 (20) million in Europe.

 

Published on 21 October 2014

According to IMS Health statistics, Finnish wholesale of human pharmaceuticals in January–September 2014 was up by 4% on the previous year at EUR 1,581 (1,520) million.

Finland is the most important individual market for Orion, generating about one-quarter of the total net sales. Orion was able to increase its sales and maintained its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by IMS Health, Orion’s wholesale of human pharmaceuticals in Finland in January–September 2014 amounted to EUR 183 (172) million, up by 6% compared with the previous year. Orion’s market share of Finnish pharmaceuticals markets was 12% (11%).

According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in June 2014 the total sales of Parkinson’s drugs in the United States were up by 9% at USD 805 million (USD 738 million in the previous 12-month period). The five largest European markets for Parkinson’s disease drugs were Germany, the United Kingdom, France, Spain and Italy. In these countries, the combined sales of Parkinson’s drugs totalled EUR 995 (969) million in the 12-month period ending in June 2014, and the average market growth was 3%. In Japan sales of Parkinson’s drugs were down by 11% at EUR 491 (554) million.

According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in June 2014 the total sales of Parkinson’s drugs containing entacapone were USD 130 (161) million in the United States and EUR 149 (154) million in the five largest European markets.

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s branded Parkinson’s drugs containing entacapone (Stalevo®, Comtess® and Comtan®) account for nearly one-fifth of the Group’s net sales. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in June 2014, sales of Orion’s branded Parkinson’s drugs in the United States were down by 60% at USD 23 (57) million. Sales were down by 3% at EUR 129 (132) million in the five largest markets in Europe, and in Japan sales were EUR 53 (63) million. The decrease in sales in Japan was due to depreciation of the yen exchange rate. Measured in terms of local currency, the market as whole and sales of Orion’s Parkinson’s drugs both grew. The market share of Orion’s branded Parkinson’s drugs was 3% in the United States, on average 13% in the five largest European markets and 11% in Japan.

According to IMS Health pharmaceutical sales statistics, sales of Precedex® intensive care sedative (dexmedetomidine) were up by 17% at USD 397 million in the 12-month period ending in June 2014 (USD 340 million in the previous 12-month period). About four-fifths of the sales amounting to USD 332 (279) million were in the United States, where Precedex sales grew by 19%. IMS Health pharmaceutical sales statistics have become more comprehensive as regards reporting of Precedex, following which the figures for the reported period and comparative period are greater than as previously.

According to IMS Health pharmaceutical sales statistics, total sales of the most common intravenous anaesthetics and intensive care sedatives (propofol, midazolam, remifentanil and dexmedetomidine) in Europe in the 12-month period ending in June 2014 were EUR 485 (474) million. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in June 2014 sales of Orion’s dexdor® intensive care sedative (dexmedetomidine) were up by 34% at EUR 24 (18) million in Europe.

Published on 29 July 2014

According to IMS Health statistics, Finnish wholesale of human pharmaceuticals in January–June 2014 was up by 4% on the previous year at EUR 1,048 (1,011) million.

Finland is the most important individual market for Orion, generating about one-quarter of the total net sales. Orion was able to increase its sales and maintained its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by IMS Health, Orion’s wholesale of human pharmaceuticals in Finland in January–June 2014 amounted to EUR 121 (116) million, up by 5% compared with the previous year. Orion’s market share of Finnish pharmaceuticals markets was 12% (11%).

According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in March 2014 the total sales of Parkinson’s drugs in the United States were up by 8% at USD 792 million (USD 730 million in the previous 12-month period). The five largest European markets for Parkinson’s disease drugs were Germany, the United Kingdom, France, Spain and Italy. In these countries, the combined sales of Parkinson’s drugs totalled EUR 993 (965) million in the 12-month period ending in March 2014, and the average market growth was 3%. In Japan sales of Parkinson’s drugs were down by 15% at EUR 494 (580) million.

According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in March 2014 the total sales of Parkinson’s drugs containing entacapone were USD 138 (173) million in the United States and EUR 151 (155) million in the five largest European markets.

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s branded Parkinson’s drugs containing entacapone (Stalevo®, Comtess® and Comtan®) account for about one-fifth of the Group’s net sales. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in March 2014, sales of Orion’s branded Parkinson’s drugs in the United States were down by 68% at USD 26 (81) million. Sales were down by 5% at EUR 128 (134) million in the five largest markets in Europe, and in Japan sales were EUR 55 (66) million. The decrease in sales in Japan was due to depreciation of the yen exchange rate. Measured in terms of local currency, the market as whole and sales of Orion’s Parkinson’s drugs both grew. The market share of Orion’s branded Parkinson’s drugs was 3% in the United States, on average 13% in the five largest European markets and 11% in Japan.

According to IMS Health pharmaceutical sales statistics, sales of Precedex® intensive care sedative (dexmedetomidine) were up by 22% at USD 378 million in the 12-month period ending in March 2014 (USD 310 million in the previous 12-month period). About four-fifths of the sales amounting to USD 316 (252) million were in the United States, where Precedex sales grew by 26%. IMS Health pharmaceutical sales statistics have become more comprehensive as regards reporting of Precedex, following which the figures for the reported period and comparative period are greater than as previously.

According to IMS Health pharmaceutical sales statistics, total sales of the most common intravenous anaesthetics and intensive care sedatives (propofol, midazolam, remifentanil and dexmedetomidine) in Europe in the 12-month period ending in March 2014 were EUR 479 (472) million. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in March 2014 sales of Orion’s dexdor® intensive care sedative (dexmedetomidine) were up by 46% at EUR 22 (15) million in Europe.

 

Published on 29 April 2014

According to IMS Health pharmaceutical sales statistics, Finnish wholesale of human pharmaceuticals in January–March 2014 was up by 3% on the previous year at EUR 513 (497) million.

Finland is the most important individual market for Orion, generating about one-quarter of the total net sales. Orion was able to increase its sales and maintained its position as leader in marketing pharmaceuticals in Finland. According to statistics collected by IMS Health, Orion’s wholesale of human pharmaceuticals in Finland in January–March 2014 amounted to EUR 59 (57) million, up by 2% compared with the previous year. Orion’s market share of Finnish pharmaceuticals markets was 11% (12%).

According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in December 2013 the total sales of Parkinson’s drugs in the United States were up by 6% at USD 763 million (USD 720 million in the previous 12-month period). The five largest European markets for Parkinson’s disease drugs were Germany, the United Kingdom, France, Spain and Italy. In these countries, the combined sales of Parkinson’s drugs totalled EUR 986 (965) million in the 12-month period ending in December 2013, and the average market growth was 2%. In Japan sales of Parkinson’s drugs were down by 17% at EUR 494 (593) million.

According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in December 2013 the total sales of Parkinson’s drugs containing entacapone were USD 144 (181) million in the United States and EUR 152 (157) million in the five largest European markets.

The most important individual therapy area for Orion is still the treatment of Parkinson’s disease. Orion’s branded Parkinson’s drugs containing entacapone (Stalevo®, Comtess® and Comtan®) account for about one-fifth of the Group’s net sales. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in December 2013, sales of Orion’s branded Parkinson’s drugs in the United States were down by 74% at USD 31 (118) million. Sales were down by 5% at EUR 130 (136) million in the five largest markets in Europe, and in Japan sales were EUR 55 (67) million. The decrease in sales in Japan was due to depreciation of the yen exchange rate. Measured in terms of local currency, the market as whole and sales of Orion’s Parkinson’s drugs both grew. The market share of Orion’s branded Parkinson’s drugs was 4% in the United States, on average 13% in the five largest European markets and 11% in Japan.

According to IMS Health pharmaceutical sales statistics, sales of Precedex® intensive care sedative (dexmedetomidine) were up by 22% at USD 327 million in the 12-month period ending in December 2013 (USD 269 million in the previous 12-month period). About four-fifths of the sales amounting to USD 266 (211) million were in the United States, where Precedex sales grew by 26%.

According to IMS Health pharmaceutical sales statistics, total sales of the most common intravenous anaesthetics and intensive care sedatives (propofol, midazolam, remifentanil and dexmedetomidine) in Europe in the 12-month period ending in December 2013 were EUR 475 (473) million. According to IMS Health pharmaceutical sales statistics, in the 12-month period ending in December 2013 sales of Orion’s dexdor® intensive care sedative (dexmedetomidine) were up by 82% at EUR 21 (12) million in Europe.